Protein kinase C isoenzymes recently emerged as interesting targets for the development of novel immunosuppressive drugs. Indeed, a PKC inhibitor is currently evaluated in clinical trials to prevent the rejection of organ transplants. Cécile Springael, MD, Research Fellow of the F.R.S.-FNRS preparing her MD-PhD under the supervision of Fabienne Willems, PhD, recently demonstrated that inhibition of protein kinase C-theta might be of special interest to inhibit the activation of T lymphocytes.

Related reference: Springael C, Thomas S, Rahmouni S, Vandamme A, Goldman M, Willems F, Vosters O. Rottlerin inhibits human T cell responses Biochem Pharmacol 2007 ; 73 : 515-525. View Abstract